Cigna Corporation (NYSE:CI) reported its Q1 results, with EPS coming in at $6.01, beating the consensus estimate of $5.17. Revenue was $44 billion, compared to the consensus estimate of $43.42 billion.
Strong quarterly results reflected solid performance across both the Evernorth and Cigna Healthcare segments. In particular, Evernorth saw sustained momentum across its specialty pharmacy business lines, as Accredo and CuraScript continued to support outsized growth in the specialty platform.
The company provided its full 2022-year outlook, expecting EPS of $22.60, compared to the consensus estimate of $22.49, and revenue of $177 billion, compared to the consensus estimate of $178.9 billion.
